Development Compound and Licensed Product Development Responsibilities Clause Samples

Development Compound and Licensed Product Development Responsibilities. Astellas will initiate Development of any Development Compound promptly upon its designation as a Development Compound and expiration of the Co-Development Option Period with respect to that Development Compound in accordance with Section 3.2(a) (Co-Development Option), and will inform PTI of the time it so initiates Development and the Indication for which such Licensed Product is being Developed, each of which will be deemed Confidential Information of Astellas. If PTI does not exercise its Co-Development Option for a Development Compound, Astellas will have the sole right and responsibility for, and will have full control and authority over, at its sole cost and expense, the Development of Development Compounds and Licensed Products for any Indication, including the right to make all strategic and tactical decisions with respect thereto, to conduct all Development activities and to establish the methods and means by which it performs such activities under this Agreement. Astellas may, in its sole discretion, delegate any work performed on Development of such Licensed Product to any of its Third Party Collaborators, or to any other Third Party consultants, clinical investigators and service providers; provided, however, that Astellas remains responsible for the performance of any Third Party Collaborators or Third Parties and, provided further, that any such delegated work is performed under a written agreement with such Third Party Collaborator or Third Party which assigns to Astellas any Inventions (to the extent possible) and contains confidentiality provisions at least as protective as those in this Agreement covering the disclosure of any information disclosed by either Party to such Third Party Collaborator or Third Party in the performance of such delegated work.
View Source

Related to Development Compound and Licensed Product Development Responsibilities

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Commercialization License Subject to the terms of this Agreement, including without limitation Section 2.2 and Theravance's Co-Promotion rights in Section 5.3.2, Theravance hereby grants to GSK, and GSK accepts, an exclusive license under the Theravance Patents and Theravance Know-How to make, have made, use, sell, offer for sale and import Alliance Products in the Territory.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection ▇▇▇▇▇; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Collaboration activities 4.1 The Collaboration Suppliers will perform the Collaboration Activities and all other obligations of this Agreement in accordance with the Detailed Collaboration Plan. 4.2 The Collaboration Suppliers will provide all additional cooperation and assistance as is reasonably required by the Buyer to ensure the continuous delivery of the services under the Call-Off Contract. 4.3 The Collaboration Suppliers will ensure that their respective subcontractors provide all cooperation and assistance as set out in the Detailed Collaboration Plan.